Leo Pharma’s FDA nod adds a challenger to Dupixent’s dominance in eczema


With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that addresses the same target. LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.